Sid Boregowda

• Designed, built, and tested mechanical-based device to isolate stromal vascular fraction from fat tissue • Selected as semifinalist, ‘ActivateBio 20’ entrepreneurship program organized by Harvard/MIT and sponsored by MassBio • Patent for predictive marker of clinical effectiveness of stem cell therapy

• Regenerative medicine approach to senile osteoporosis: Solved cellular and molecular characteristics of skeletal stem cell exhaustion in osteoporosis. Using global and single cell transcriptomic approach, identified loss of alpha 2 macroglobulin (A2M) expression as key cause of skeletal stem cell exhaustion in a mouse model of osteoporosis • Leading A2M project to a cell-based screening to identify glucocorticoid receptor modulators to promote A2M expression by skeletal stem cells with an aim of curing multicausal osteoporosis • Elucidated molecular and cellular mechanisms of novel target of Huntington’s disease and Taopathies, Rhes. Proposed emerging therapeutic modalities to target Rhes gene within the striatum. • Lab safety co-ordinator • Mentor - MD/PhD students, Technicians, Undergraduate interns

Scripps President’s Postdoctoral Fellow Sandelman Travel Award • Regenerative medicine approach to diabetic osteoporosis: Successfully lead development of IP6K1 as a target for diabetic osteoporosis and senile osteoporosis through in vitro cell and molecular biology, drug screening, and preclinical studies • Collaborating with Calibr to screen for IP6K1 inhibitors using ReFrame Library donated by Gates Foundation. • Stem cell maintenance: Using genetic and transcriptomic approaches, established the role of P53-TWIST2-PPARG axis in mesenchymal stem cell maintenance and differentiation • Lab safety co-ordinator • Mentor - MD/PhD students, Technicians, Undergraduate interns

• 800 Quantitative GRE • Oxidative stress in stem cells: Solved the in vitro culture problem of mouse mesenchymal stem cells that plagued mouse cell biology field for 50 years with a method for reliable isolation and culture expansion of mouse mesenchymal stem cells without the risk of in vitro transformation or cell death using closed low oxygen system • Stem cell therapy: Addressed a lack of predictive value for therapeutic outcomes of complex cell therapies by developing a clinical indication prediction (CLIP) scale for mesenchymal stem cells using TWIST1 expression as biomarker. • CLIP scale provided a simplified model for cell therapy which is not amenable to classical pharmacology and pharmacokinetics • Resolved similarities and differences between paracrine-based therapeutic activities of mesenchymal stem cell isolated from multiple human donors using in vitro and in vivo inflammation and vascular models

• 6th rank, all India entrance test to gain entry into the master’s program • Indian Council of Agriculture Research’s Junior Research Fellow in the Department of Veterinary Pharmacology and Toxicology • Established a 20% longer withdrawal time using HPLC-MS/MS approach for antibiotics administered with NSAIDs before meat is fit for human consumption

Education and training in veterinary medicine, animal husbandry and management. Practiced small and large animal medicine, surgery, and gynecology.